Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study

Vavricka, Stephan R.; Gubler, Martin; Gantenbein, Claudine; More

Inflammatory Bowel Diseases . 23(7):1174-1181, July 2017.

Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease

Mottet, Christian; Schoepfer, Alain M.; Juillerat, Pascal; More

Inflammatory Bowel Diseases . 22(11):2733-2747, November 2016.

Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort

Vavricka, Stephan R.; Rogler, Gerhard; Gantenbein, Claudine; More

Inflammatory Bowel Diseases . 21(8):1794-1800, August 2015.

A Shift From Oral to Intravenous Iron Supplementation Therapy Is Observed Over Time in a Large Swiss Cohort of Patients With Inflammatory Bowel Disease

Vavricka, Stephan R.; Schoepfer, Alain M.; Safroneeva, Ekaterina; More

Inflammatory Bowel Diseases . 19(4):840-846, March-April 2013.

Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes

Schoepfer, Alain M.; Beglinger, Christoph; Straumann, Alex; More

Inflammatory Bowel Diseases . 19(2):332-341, February 2013.

Systematic Assessment of Factors Influencing Preferences of Crohn's Disease Patients in Selecting an Anti‐Tumor Necrosis Factor Agent (CHOOSE TNF TRIAL)

Vavricka, Stephan R.; Bentele, Nicoletta; Scharl, Michael; More

Inflammatory Bowel Diseases . 18(8):1523-1530, August 2012.

Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease

Vavricka, Stephan R.; Spigaglia, Sabrina M.; Rogler, Gerhard; More

Inflammatory Bowel Diseases . 18(3):496-505, March 2012.

Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26‐week data of the FACTS II survey

Vavricka, Stephan R.; Schoepfer, Alain M.; Bansky, Georg; More

Inflammatory Bowel Diseases . 17(7):1530-1539, July 2011.

Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey†

Schoepfer, Alain M.; Vavricka, Stephan R.; Binek, Janek; More

Inflammatory Bowel Diseases . 16(6):933-938, June 2010.